Company Profile
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company s operating segments include Simulations Plus, Inc; Cognigen Corporation; DILIsym, and Lixoft. It generates maximum revenue from Simulations Plus, Inc segment. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Predictor which is a computer program that takes molecular structures as inputs; MedChem Designer and MedChem Studio.
News Category Global Banking & Finance Reviews
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides
Simulations Plus Enters New Funded Collaboration to Enhance Top-Rated GastroPlus® ACAT™ Model for Oral Absorption of Peptides Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it has entered into a new funded collaboration with a large pharmaceutical company to add novel mechanisms for oral peptide formulations within the top-rated GastroPlus Advanced Compartmental Absorption and Transit (ACAT„¢) mechanistic model. Our partner, a frequent user of the GastroPlus platform across multiple research sites worldwide, has a growing portion of their development pipeline focused on therapeutic peptides and proteins, said Dr. Viera Lukacova, chief scientist at Simul
PUNE, INDIA, INDIA, December 27, 2020 /EINPresswire.com/ Biosimulation Market - 2019-2025
Report Description:
Biosimulation is a technique in which computer programs are used for the simulation of biological processes. Biosimulation has wide reaching applications in the field of drug discovery and development of new drugs. It is a tool used for prediction and biosimulation is used to predict the future outcomes of current experiments related to discovery and development of new drugs. The process of drug discovery and development is a costly one, and the failure of the drug molecule in the late phase of drug development translates into a huge wastage of time, money and other resources. Hence, there is a need of a predictive tool that will aid in predicting the future outcomes of drug development by simulation of the biological processes involved. This is the most important factor driving the global biosimulation market. The other factors supporting the growth of the biosimulation
The Biosimulation Market To Witness A Discerning Growth Between 2022
Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili. In the process of biosimulation, the computer aided mathematical models are used to simulate the biological processes. Biosimulation is an important part of systems biology and helps in the discovery and development of new drugs, in the area of drug metabolism and in the modeling of biomedical systems that are complex. There is a growing demand for reduction in the cost of discovery of new drugs and the risk of failure at a later stage in the development of new drugs is too high. In order to counter such problems, biosimulation is used as a predictive tool and it helps in the prediction of the future outcomes of the drug development by simulation of the biological processes involved.